254 related articles for article (PubMed ID: 18322403)
1. Lithium, a potential protective drug in Alzheimer's disease.
Engel T; Goñi-Oliver P; Gómez de Barreda E; Lucas JJ; Hernández F; Avila J
Neurodegener Dis; 2008; 5(3-4):247-9. PubMed ID: 18322403
[TBL] [Abstract][Full Text] [Related]
2. Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors.
Avila J; Wandosell F; Hernández F
Expert Rev Neurother; 2010 May; 10(5):703-10. PubMed ID: 20420491
[TBL] [Abstract][Full Text] [Related]
3. GSK-3 inhibitors for Alzheimer's disease.
Avila J; Hernández F
Expert Rev Neurother; 2007 Nov; 7(11):1527-33. PubMed ID: 17997701
[TBL] [Abstract][Full Text] [Related]
4. Lithium down-regulates tau in cultured cortical neurons: a possible mechanism of neuroprotection.
Rametti A; Esclaire F; Yardin C; Cogné N; Terro F
Neurosci Lett; 2008 Mar; 434(1):93-8. PubMed ID: 18289787
[TBL] [Abstract][Full Text] [Related]
5. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
Ferrer I; Barrachina M; Puig B
Acta Neuropathol; 2002 Dec; 104(6):583-91. PubMed ID: 12410379
[TBL] [Abstract][Full Text] [Related]
6. GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer's disease?
Martinez A; Perez DI
J Alzheimers Dis; 2008 Oct; 15(2):181-91. PubMed ID: 18953107
[TBL] [Abstract][Full Text] [Related]
7. Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert.
Engel T; Goñi-Oliver P; Lucas JJ; Avila J; Hernández F
J Neurochem; 2006 Dec; 99(6):1445-55. PubMed ID: 17059563
[TBL] [Abstract][Full Text] [Related]
8. Propentofylline attenuates tau hyperphosphorylation in Alzheimer's Swedish mutant model Tg2576.
Chauhan NB; Siegel GJ; Feinstein DL
Neuropharmacology; 2005 Jan; 48(1):93-104. PubMed ID: 15617731
[TBL] [Abstract][Full Text] [Related]
9. Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease.
Medina M; Avila J
Curr Pharm Des; 2010; 16(25):2790-8. PubMed ID: 20698823
[TBL] [Abstract][Full Text] [Related]
10. Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles.
Caccamo A; Oddo S; Tran LX; LaFerla FM
Am J Pathol; 2007 May; 170(5):1669-75. PubMed ID: 17456772
[TBL] [Abstract][Full Text] [Related]
11. Flow cytometry-based method to analyze the change in Tau phosphorylation in a hGSK-3beta and hTau over-expressing EcR-293 cell line.
Kurko D; Boros A; Dezso P; Urbányi Z; Sárvári M; Nagy J; Szombathelyi Z; Szendrei GI
Neurochem Int; 2006 Apr; 48(5):374-82. PubMed ID: 16420965
[TBL] [Abstract][Full Text] [Related]
12. Lithium may be useful in the prevention of Alzheimer's disease in individuals at risk of presenile familial Alzheimer's disease.
Yeh HL; Tsai SJ
Med Hypotheses; 2008 Dec; 71(6):948-51. PubMed ID: 18760542
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo.
Noble W; Planel E; Zehr C; Olm V; Meyerson J; Suleman F; Gaynor K; Wang L; LaFrancois J; Feinstein B; Burns M; Krishnamurthy P; Wen Y; Bhat R; Lewis J; Dickson D; Duff K
Proc Natl Acad Sci U S A; 2005 May; 102(19):6990-5. PubMed ID: 15867159
[TBL] [Abstract][Full Text] [Related]
14. Neurofibrillary degeneration in Alzheimer's disease: from molecular mechanisms to identification of drug targets.
Pei JJ; Sjögren M; Winblad B
Curr Opin Psychiatry; 2008 Nov; 21(6):555-61. PubMed ID: 18852562
[TBL] [Abstract][Full Text] [Related]
15. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study.
Hampel H; Ewers M; Bürger K; Annas P; Mörtberg A; Bogstedt A; Frölich L; Schröder J; Schönknecht P; Riepe MW; Kraft I; Gasser T; Leyhe T; Möller HJ; Kurz A; Basun H
J Clin Psychiatry; 2009 Jun; 70(6):922-31. PubMed ID: 19573486
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotective effects of lithium: implications for the treatment of Alzheimer's disease and related neurodegenerative disorders.
Forlenza OV; De-Paula VJ; Diniz BS
ACS Chem Neurosci; 2014 Jun; 5(6):443-50. PubMed ID: 24766396
[TBL] [Abstract][Full Text] [Related]
17. Newly developed glycogen synthase kinase-3 (GSK-3) inhibitors protect neuronal cells death in amyloid-beta induced cell model and in a transgenic mouse model of Alzheimer's disease.
Noh MY; Chun K; Kang BY; Kim H; Park JS; Lee HC; Kim YH; Ku S; Kim SH
Biochem Biophys Res Commun; 2013 May; 435(2):274-81. PubMed ID: 23632329
[TBL] [Abstract][Full Text] [Related]
18. Multiple roles for glycogen synthase kinase-3 as a drug target in Alzheimer's disease.
Huang HC; Klein PS
Curr Drug Targets; 2006 Nov; 7(11):1389-97. PubMed ID: 17100579
[TBL] [Abstract][Full Text] [Related]
19. Pivotal role of glycogen synthase kinase-3: A therapeutic target for Alzheimer's disease.
Maqbool M; Mobashir M; Hoda N
Eur J Med Chem; 2016 Jan; 107():63-81. PubMed ID: 26562543
[TBL] [Abstract][Full Text] [Related]
20. Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration.
Leroy K; Yilmaz Z; Brion JP
Neuropathol Appl Neurobiol; 2007 Feb; 33(1):43-55. PubMed ID: 17239007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
